Targeted radiotherapy for pancreatic cancer
Optimized targeted radiotherapy of pancreatic cancer
This study is looking at a new treatment for advanced pancreatic cancer by using a special antibody called TAB004 that helps deliver radiation directly to the cancer cells, making the treatment more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncotab, INC NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project ID | NIH-11069517 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with a low survival rate. The approach involves developing a specific antibody, TAB004, that targets a protein found on the surface of cancer cells, allowing for more effective delivery of radiotherapy. By overcoming the challenges posed by the tumor's stroma, which hinders drug delivery, this research aims to enhance the effectiveness of treatment for patients with advanced pancreatic cancer. The study will explore the use of a fully humanized version of the antibody for targeted radiotherapy and imaging.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with advanced or metastatic disease.
Not a fit: Patients with early-stage pancreatic cancer who can undergo surgical removal of their tumors may not benefit from this targeted therapy approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies in other cancer types, indicating potential for success in this novel approach for pancreatic cancer.
Where this research is happening
Charlotte, United States
- Oncotab, INC — Charlotte, United States (Active)
Researchers
- Principal investigator: Mukherjee, Pinku — Oncotab, INC
- Study coordinator: Mukherjee, Pinku
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.